摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-chloro-1-(3-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidine | 852314-01-3

中文名称
——
中文别名
——
英文名称
4-chloro-1-(3-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidine
英文别名
4-chloro-1-(3-chlorophenyl)pyrazolo[3,4-d]pyrimidine
4-chloro-1-(3-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidine化学式
CAS
852314-01-3
化学式
C11H6Cl2N4
mdl
MFCD06740791
分子量
265.101
InChiKey
HTCSVFHWWKNXID-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    360.4±42.0 °C(Predicted)
  • 密度:
    1.58±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    17
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    43.6
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    [EN] PYRAZOLOPYRIMIDINES AS ANTI - HEPATITS C AGENTS
    [FR] PYRAZOLOPYRIMIDINES UTILISES COMME AGENTS ANTI-HEPATITE C
    摘要:
    式(I)的吡唑啉衍生物,或其药用可接受的盐,被发现对丙型肝炎感染具有活性,其中:R1为C6-C10芳基,5-到10-成员杂芳基,-(C1-C4烷基)-(C6-C10芳基)或-(C1-C4烷基)-(5-到10-成员杂芳基);R2为C6-C10芳基,C3-C6碳环烷基,5-到10-成员杂芳基或5-到10-成员杂环烷基基团,该基团可选择地与C6-C10芳基,C3-C6碳环烷基,5-到10-成员杂芳基或5-到10-成员杂环烷基环融合;X为-NR'-,-NR'-CO-NR''-,-NR'-L,或-NR'-CO-L-,其中R'和R''相同或不同,分别代表氢或C1-C6烷基,L代表C1-C6烷基基团,R1和R2取代基中的芳基,杂芳基,杂环烷基和碳环烷基基团未取代或通过1、2或3个卤素、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基、C1-C4卤代烷氧基、氰基、硝基、C6-C10芳基、C3-C6碳环烷基、5-到10-成员杂环烷基、5-到10-成员杂芳基、-NR'-CO2-R''、-CO2R''、-COR'''-NR'-CO-R'''、-CONR'R''、SO2NR'R''、SO2R'''和-O-(CH2)n-R'''取代。
    公开号:
    WO2005047288A1
  • 作为产物:
    描述:
    4,6-dichloro-5-{[2-(3-chlorophenyl)hydrazono]methyl}pyrimidine 以 乙腈 为溶剂, 反应 0.33h, 以92%的产率得到4-chloro-1-(3-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidine
    参考文献:
    名称:
    Synthesis of 1,4-Disubstituted Pyrazolo[3,4-d]pyrimidines from 4,6-Dichloropyrimidine-5-carboxaldehyde: Insights into Selectivity and Reactivity
    摘要:
    Strategies for carrying out the reaction of 4,6-dichloropyrimidine-5-carboxaldehyde with both aromatic and aliphatic hydrazines to generate 1-substituted 4-chloropyrazolo[3,4-d]pyrimidines in a selective, high-yielding, and operationally simple manner are presented. For aromatic hydrazines, the reaction is performed at a high temperature in the absence of an external base. For aliphatic hydrazines, the reaction proceeds at room temperature in the presence of an external base. The observed selectivity and reactivity trends are rationalized through consideration of the proposed reaction mechanism. The 1-substituted 4-chloropyrazolo[3,4-d]pyrimidine products serve as versatile synthetic intermediates, through further functionalization of the 4-chloride moiety, enabling the rapid generation of a structurally diverse array of 1,4-disubstituted pyrazolo[3,4-d]pyrimidines.
    DOI:
    10.1055/s-0033-1338862
点击查看最新优质反应信息

文献信息

  • [EN] PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE SOUS FORME DE PYRAZOLOPYRIMIDINES
    申请人:SMITHKLINE BEECHAM CORP
    公开号:WO2004009602A1
    公开(公告)日:2004-01-29
    The present invention relates generally to inhibitors of the kinases and more particularly to novel pyrazolopyrimidine compounds.
    本发明一般涉及激酶的抑制剂,更具体地涉及新型吡唑嘧啶化合物。
  • Selective Synthesis of 1-Substituted 4-Chloropyrazolo[3,4-<i>d</i>]pyrimidines
    作者:Suresh Babu、Christie Morrill、Neil G. Almstead、Young-Choon Moon
    DOI:10.1021/ol4005382
    日期:2013.4.19
    Strategies for carrying out the reaction of 4,6-dichloropyrimidine-5-carboxaldehyde with various hydrazines to generate 1-substituted 4-chloropyrazolo[3,4-d]pyrimidines in a selective and high-yielding manner are presented. For aromatic hydrazines, the reaction is performed in the absence of an external base, which promotes exclusive hydrazone formation. The hydrazones subsequently cyclize at an elevated temperature to form the desired pyrazolo[3,4-d]pyrimidine products. For aliphatic hydrazines, the reaction sequence proceeds as a single step in the presence of an external base.
  • PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS
    申请人:SmithKline Beecham Corporation
    公开号:EP1551841A1
    公开(公告)日:2005-07-13
查看更多